Clinical trials in Leiden – page 69

1 938 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Leiden at a glance

1 938

clinical trials

Research sites4

Quick filters

1 938 trials in Leiden

Open in trial search

Squamous cell carcinoma of head and neck

Not yet recruiting

Study on Sodium Thiosulfate to Prevent Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin Treatment

Registered drugNo placebo

Study on Sodium Thiosulfate to Prevent Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Sodium Thiosulfate
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Novartis Pharma AG

Contact Research Centre

Compartment syndrome

Not yet recruiting

Botulinum toxin type A versus sodium chloride for patients with chronic exertional compartment syndrome of the leg

Registered drug

Botulinum toxin type A versus sodium chloride for patients with chronic exertional compartment syndrome of the leg

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Sodium Chloride
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

HER2 positive breast cancer

Not yet recruiting

Neoadjuvant Study of Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in Patients with Stage II‑IIIA HER2‑Positive Breast Cancer

InvestigationalNo placebo

Neoadjuvant Study of Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in Patients with Stage II‑IIIA HER2‑Positive Breast Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Zongertinib
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Cholangiocarcinoma+1

Not yet recruiting

Safety and feasibility study of hepatic arterial vs IV oxaliplatin in patients with colorectal liver metastases and cholangiocarcinoma (oxaliplatin drug combination)

Registered drugNo placebo

Safety and feasibility study of hepatic arterial vs IV oxaliplatin in patients with colorectal liver metastases and cholangiocarcinoma (oxaliplatin drug combination)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Bladder transitional cell carcinoma stage I

Not yet recruiting

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Registered drugNo placebo

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

Influenza vaccine efficacy in elderly
Yellow fever prophylaxis
Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

Parkinson's Disease treatments
CNS response analysis
Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

Advanced solid tumors
Gastric cancer diagnosis
Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Back to the Netherlands All countries